Sangamo Therapeutics to Acquire Regulatory T Cell Leader TxCell for €72 Million

Sangamo Therapeutics (Nasdaq: SGMO) has announced it is acquiring TxCell S.A. (ENXTPA: TXCL) in a deal worth approximately €72 million. The deal is expected to be completed by the fourth quarter of 2018.

This acquisition will combine Sangamo’s unique ex vivo (outside the body) gene editing technology with TxCell’s CAR-Treg prowess, making Sangamo a new global leader in the Treg sector.

Regulatory T Cells (Tregs)

Regulatory T cells, known as Tregs, are a subset of T cells that impact the immune system, maintain tolerance to self-antigens, and prevent autoimmune disease.

Based in Valbonne, France, TxCell is a specialty company that develops unique cellular immunotherapy platforms based on antigen-specific regulatory T cells (Tregs). It is the only clinical-stage cellular therapy company dedicated to the science of regulatory T lymphocytes (Tregs).

Treg Clinical Trial

The companies have also announced that they intend to initiate the first CAR-Treg clinical trial by 2019.

As stated in the company announcement, “In 2019, Sangamo expects to submit a clinical trial authorization application in Europe for TxCell’s first CAR-Treg investigational product candidate for solid organ transplant, and to initiate a Phase 1/2 clinical trial later in the year. In addition, Sangamo intends to use its zinc finger nuclease (ZFN) gene editing technology to develop next-generation autologous and allogeneic CAR-Treg cell therapies for use in treating autoimmune diseases.”

For additional details about the deal, view Sangamo’s press release. 

Related Product: Global Database of CAR-T Cell Therapy Companies (2018)